N-Power Medicine, a Redwood City, CA-based company which specializes in clinical trial processes, raised an undisclosed amount in Series B funding.
The round, which brought the total amount to $72M, was led by Merck Global Health Innovation Fund, with participation from a US-based healthcare focused investor.
N-Power Medicine is also collaborating with Merck, known as MSD outside the United States and Canada, to enable a greater number of oncologists, and the patients they care for, to participate in clinical research.
The company intends to use the funds for the expansion of its network of oncology clinics and biopharmaceutical company collaborations leveraging its platform for integrating clinical research into everyday patient care.
Founded in 2021 and led by CEO Mark Lee, N-Power Medicine aims to accelerate the drug development process and expedite patients’ access to innovative therapies. It has developed an integrated platform providing a single workflow for both clinical trial and routine patient management. N-Power’s “human in the loop” model, consisting of virtual and on-site staff assisted by AI-enabled workflow automation, supports oncologists in generating research-ready data for all patients in the practice and in preparing standardized clinical documentation for the medical record.
Its platform consists of three fundamental components:
- The Kaleido™ Registry, which collects prospective, real-time, standardized patient data expressly designed to support clinical trials and drug development. To date, over 7,000 patients have consented and enrolled in the registry.
- The point of care technology, which enables seamless workflow management and provides an access to patient data and insights while ensuring compliance with regulatory requirements and quality standards for prospective clinical research.
- On-site and virtual experts, which support oncologists and research staff to operationalize the Registry and support clinical documentation, while reducing their overall workload, allowing them to focus on patient care and research.
With all patients participating in the Registry, standardized data collection readily enables actionable insights for clinical research, such as real-time, proactive identification of trial-eligible patients as well as patient characteristics and outcomes which inform trial design.
FinSMEs
01/07/2024